< 2004 News Listings Memory Pharmaceuticals Corp. Announces Pricing of Initial Public Offering MONTVALE, NJ, April 5, 2004 PRNewswire-FirstCall via COMTEX Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced today the pricing of its initial public offering of 5,000,000 shares at $7.00 per share. All of the shares are being offered by Memory Pharmaceuticals. The shares will trade on the Nasdaq National Market under the symbol "MEMY". UBS Investment Bank is acting as the sole book-runner. SG Cowen Securities Corporation is acting as co-lead manager, and Banc of America Securities LLC and Fortis Securities LLC are acting as co-managers. Memory Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock to cover over-allotments, if any. Copies of the final prospectus related to the offering may be obtained, when available, from UBS Investment Bank, ECMG Syndicate Department, 299 Park Avenue, New York, NY 10171. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. About the Company Memory Pharmaceuticals Corp. is a biopharmaceutical company focused on the development of innovative drug candidates for the treatment of central nervous system, or CNS, conditions that exhibit significant impairment of memory and other cognitive functions. These conditions include neurological diseases associated with aging, such as Alzheimer's disease, vascular dementia and mild cognitive impairment, and also include certain psychiatric disorders such as depression and schizophrenia. SOURCE: Memory Pharmaceuticals Corp.
	Copyright ©2007 Rho Capital Partners, Inc.